New COVID vaccine shows early promise in safety testing
NCT ID NCT05408312
Summary
This early-stage study tested the safety and immune response of a new COVID-19 vaccine called GEN2 in 234 healthy adults. Researchers gave different versions of the vaccine to volunteers aged 18 and older to check for side effects and measure how well it triggered protective antibodies. The main goal was to see if the vaccine was safe enough to move to larger testing phases.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 PNEUMONIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ning ling Center for Disease Control and Prevention
Shangqiu, Henan, China
Conditions
Explore the condition pages connected to this study.